Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the development of non-myeloablative stem cell transplants, which may expand the safe treatment range of allogeneic SCT, but presents no new clinical results.

This study found that autologous nonmyeloablative hematopoietic stem cell transplantation may help some newly-onset type 1 diabetes patients become insulin-free, although gastrointestinal and other mild side effects were observed.

This study found that pediatric HSCT recipients, especially those with chronic graft-versus-host disease, are at risk for developing various nonmalignant late cutaneous changes such as vitiligo, psoriasis, alopecia, and nail changes.

This study found that age is the most significant risk factor for hemorrhagic cystitis after hematopoietic stem-cell transplantation, with additional risk factors including cyclophosphamide-based prophylaxis and, among male recipients, prostatic hyperplasia.

This study found that in patients undergoing allogeneic hematopoietic stem-cell transplantation, older age significantly increases the risk of hemorrhagic cystitis, especially in males, who are also affected by prostatic hyperplasia.